AARTIDRUGS

Aarti Drugs Share Price

₹475.90 +52.35 (12.36%)

25 Dec, 2024 00:33

SIP TrendupStart SIP in AARTIDRUGS

Start SIP

Performance

  • Low
  • ₹421
  • High
  • ₹498
  • 52 Week Low
  • ₹420
  • 52 Week High
  • ₹635
  • Open Price₹424
  • Previous Close₹424
  • Volume1,231,386

Investment Returns

  • Over 1 Month + 5.93%
  • Over 3 Month -10.6%
  • Over 6 Month -6.62%
  • Over 1 Year -4.72%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarti Drugs for Steady Growth!

Invest Now

Aarti Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.5
  • PEG Ratio
  • -1.8
  • Market Cap Cr
  • 4,344
  • P/B Ratio
  • 3.4
  • Average True Range
  • 15.24
  • EPS
  • 16.56
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -9.84
  • RSI
  • 61.49
  • MFI
  • 56.59

Aarti Drugs Financials

Aarti Drugs Technicals

EMA & SMA

Current Price
₹475.90
+ 52.35 (12.36%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹449.11
  • 50 Day
  • ₹467.38
  • 100 Day
  • ₹485.00
  • 200 Day
  • ₹495.12

Resistance and Support

464.88 Pivot Speed
  • R3 585.07
  • R2 541.33
  • R1 508.62
  • S1 432.17
  • S2 388.43
  • S3 355.72

What's your outlook on Aarti Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Drugs Ltd. is a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), formulations, and intermediates. It operates in therapeutic segments like antibiotics, anti-diabetics, and cardiovascular, serving global markets with over 50% of revenue from exports.

Aarti Drugs has an operating revenue of Rs. 2,379.60 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of 9% is okay, ROE of 13% is good. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 26 which is a POOR score indicating inconsistency in earnings, a RS Rating of 13 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-08-26 Buy Back of Shares
2024-07-26 Quarterly Results
2024-05-03 Audited Results
2024-01-24 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-02-06 INTERIM Rs.1.00 per share(10%)Interim Dividend
2023-02-08 INTERIM Rs.1.00 per share(10%)Interim Dividend
2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend

Aarti Drugs F&O

Aarti Drugs Shareholding Pattern

55.64%
6.25%
0.08%
2.5%
0%
24.8%
10.73%

About Aarti Drugs

  • NSE Symbol
  • AARTIDRUGS
  • BSE Symbol
  • 524348
  • Managing Director
  • Mr. Rashesh C Gogri
  • ISIN
  • INE767A01016

Similar Stocks to Aarti Drugs

Aarti Drugs FAQs

Aarti Drugs share price is ₹475 As on 25 December, 2024 | 00:19

The Market Cap of Aarti Drugs is ₹4343.5 Cr As on 25 December, 2024 | 00:19

The P/E ratio of Aarti Drugs is 28.5 As on 25 December, 2024 | 00:19

The PB ratio of Aarti Drugs is 3.4 As on 25 December, 2024 | 00:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23